The Dingli Clinical College of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Department of Surgical Oncology, Wenzhou Central Hospital, Wenzhou, Zhejiang, China.
Cell Prolif. 2024 May;57(5):e13592. doi: 10.1111/cpr.13592. Epub 2023 Dec 29.
Cancer-associated fibroblasts (CAFs), a phenotypically and functionally heterogeneous stromal cell, are one of the most important components of the tumour microenvironment. Previous studies have consolidated it as a promising target against cancer. However, variable therapeutic efficacy-both protumor and antitumor effects have been observed not least owing to the strong heterogeneity of CAFs. Over the past 10 years, advances in single-cell RNA sequencing (scRNA-seq) technologies had a dramatic effect on biomedical research, enabling the analysis of single cell transcriptomes with unprecedented resolution and throughput. Specifically, scRNA-seq facilitates our understanding of the complexity and heterogeneity of diverse CAF subtypes. In this review, we discuss the up-to-date knowledge about CAF heterogeneity with a focus on scRNA-seq perspective to investigate the emerging strategies for integrating multimodal single-cell platforms. Furthermore, we summarized the clinical application of scRNA-seq on CAF research. We believe that the comprehensive understanding of the heterogeneity of CAFs form different visions will generate innovative solutions to cancer therapy and achieve clinical applications.
癌症相关成纤维细胞 (CAFs) 是肿瘤微环境中最重要的组成部分之一,是一种表型和功能均具有异质性的基质细胞。先前的研究已经证实,CAFs 是一种很有前途的抗癌靶点。然而,由于 CAFs 的强异质性,观察到了可变的治疗效果——既有促进肿瘤的作用,也有抗肿瘤的作用。在过去的 10 年中,单细胞 RNA 测序 (scRNA-seq) 技术的进步对生物医学研究产生了巨大影响,使我们能够以前所未有的分辨率和通量分析单细胞转录组。具体来说,scRNA-seq 有助于我们理解不同 CAF 亚型的复杂性和异质性。在这篇综述中,我们讨论了 CAF 异质性的最新知识,重点是从 scRNA-seq 的角度来研究新兴的整合多模态单细胞平台的策略。此外,我们总结了 scRNA-seq 在 CAF 研究中的临床应用。我们相信,从不同视角全面了解 CAFs 的异质性将为癌症治疗带来创新解决方案,并实现临床应用。